We first analyzed published TIL TCR beta chain (TCRβ) repertoires obtained before and after anti-PD-1 immunotherapy for two cohorts comprising 21 and 8 patients with cutaneous melanoma (Riaz et al., 2017; Tumeh et al., 2014). This evidence concerns the gene TRBV21-1 and cutaneous melanoma.